Clinical Supply of Product Sample Clauses

Clinical Supply of Product. (s) Roche shall be responsible at its own expense for the manufacture and supply of clinical supplies of the Product(s).
Sample 1Sample 2Sample 3
AutoNDA by SimpleDocs
Clinical Supply of Product. ArQule shall supply, either by itself or through a Third Party, at its own cost all clinical supply of each Optioned Compound, Product and placebo to be used in the Territory through the date of the Option Exercise, either by itself or through a Third Party. As of the date of Option Exercise, ArQule shall supply, or cause to be supplied, to Roche its clinical requirements of Optioned Compound(s) and Product(s) and placebo, provided that (i) such requirements shall be supplied to Roche at ArQule's direct manufacturing costs and allocation of manufacturing overhead, and (ii) ArQule's supply obligation shall not continue for more than * after Option Exercise, and (iii) ArQule shall maintain the same Product(s) and Optioned Compound(s) and placebo quality and specifications as immediately prior to Option Exercise, and (iv) Roche shall use Reasonable Diligence in effecting a transfer as soon as practicable of Product(s) and Optioned Compound(s) and placebo manufacturing activities from ArQule to Roche. ArQule shall also transfer to Roche a manufacturing transfer package that will enable Roche to manufacture the Product(s) and Optioned Compound(s) and placebo in a timely manner. After transition of manufacturing to Roche as contemplated in the preceding paragraph, Roche shall supply either by itself or through a Third Party at its own cost all of its clinical supply of Optioned Compound, Product and placebo. The Parties shall cooperate in all reasonable respects relating to the transition of manufacturing activities from ArQule to Roche.
Sample 1
Clinical Supply of Product. RAPT shall be responsible for the synthesis and supply to Hanmi, and Hanmi shall purchase and pay for, the quantities of Product specified on Exhibit F solely for the testing of Product in the performance of [***] in accordance with the Development Plan and the timelines described on Exhibit F, provided that such obligation to supply in the People’s Republic of China shall only begin after [***]. Hanmi shall inspect all such Product and notify RAPT in writing as soon as possible, but in no event more than [***] after delivery to Hanmi or its designee, of [***]; provided that [***]. Hanmi shall be responsible for any sourcing of clinical supply of any other active ingredient [***] for any combination studies in the Territory by Hanmi, its Affiliates or Sublicensees. For quantities of Product delivered by RAPT to Hanmi in accordance with this Section 6.2, Hanmi shall pay to RAPT the Supply Price within [***] of delivery and receipt of an invoice. All shipment and handling of Products from RAPT to Hanmi under this Agreement shall be [***].
Sample 1
Clinical Supply of Product 
Sample 1Sample 2Sample 3See All (6)

Related to Clinical Supply of Product

  • Supply of Product The JDC shall be responsible for determining the sources of, and arrangements for, the manufacture and supply of Products that the JDC believes will result in long-term profit maximization for such Products. The JDC shall endeavor to [ * ].

  • Clinical Supply Takeda will provide to Licensee[***] the amount of TAK-385 Licensed Compound or TAK-385 Licensed Products needed by Licensee to complete all Clinical Trials contemplated by the TAK-385 Development Plan (estimated by Licensee as of the Effective Date to be [***]), solely to the extent that Takeda can supply such TAK-385 [***] = Portions of this exhibit have been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment requested under 17 C.F.R. Sections 200.80(b)(4) and 230.406. Licensed Compound or TAK-385 Licensed Products (a) from its supply of TAK-385 Licensed Compound or TAK-385 Licensed Products in existence as of the Effective Date and which supply can be used for its intended purposes without further re-processing (the “Initial Clinical Supply”) and (b) after retaining the amount needed by Takeda for Clinical Trials in the Takeda Territory. Takeda will also provide to Licensee, at [***] any additional supplies of TAK-385 Licensed Compound or TAK-385 Licensed Products in excess of the Initial Clinical Supply needed by Licensee to complete all Clinical Trials contemplated by the TAK-385 Development Plan. Within [***] days after the Effective Date, the Parties will enter into a manufacturing and supply agreement (the “Takeda Clinical Manufacturing and Supply Agreement”), which will govern the terms and conditions of the Manufacturing and supply of the TAK-385 Licensed Compound and TAK-385 Licensed Products (including the Initial Clinical Supply) by Takeda to Licensee for Development purposes, including the exact quantities and the timelines for delivery. The Parties will negotiate the terms and conditions of such Takeda Clinical Manufacturing and Supply Agreement in good faith for a period of [***] days (as may be extended upon agreement of the Parties). As part of the negotiation related to the Takeda Clinical Manufacturing and Supply Agreement, the Parties shall discuss in good faith the ability of Takeda to supply to Licensee [***]. If the Parties have not entered into a definitive agreement within such negotiation period, then the final terms and conditions of such agreement will be resolved in accordance with Section 8.2 (Arbitration for Failure to Agree).

  • Supply of Products TheraSense shall be responsible for the ------------------ manufacture of FreeStyle Products for sale to Nipro.

  • Manufacture of Product Prior to commercialization of the Product, the Parties may, if appropriate for both parties, negotiate in good faith a manufacturing and supply agreement to provide for Licensor to fulfill the manufacturing requirements of Licensee for Product for sale in the European market. The cost of such manufacturing shall not be greater than * percent (*%) of the cost of any competitor cGMP contract manufacturing facility that proposes to manufacturer the Product for Licensee. * Confidential information has been omitted and filed confidentially with the Securities and Exchange Commission.

  • Development of Products (a) During the term of this Agreement, ViewRay may from time to time seek services from PEKO with respect to the development of certain Products that can be incorporated into the ViewRay Renaissance™ MRI-guided radiation therapy system. For each Program to be undertaken by PEKO pursuant to this Agreement, the parties will prepare a “Work Statement” and agree to said “Work Statement” in substantially the form attached as Attachment 1. Each Work Statement will describe: (i) the (i) services that PEKO will be responsible for providing to ViewRay and the deliverables that PEKO will be responsible for delivering to ViewRay (“Deliverable(s)”), (ii) delivery schedule for the Deliverables, (iii) pricing terms, (iv) work plan for the Program, and (v) ViewRay’s responsibilities in connection with the Program. Each Work Statement will be prepared based upon the requirements and information provided to PEKO by ViewRay. A separate Work Statement will be required for each Program; and each Work Statement will become subject to this Agreement only when mutually agreed and signed by ViewRay and PEKO.

  • Manufacture of Products All Products marketed through Grantor's Web ------------------------- Site shall be manufactured, packaged, prepared, and shipped in accordance with the specifications and requirements described on Exhibit A hereto as it may be modified from time to time. Quality control standards relating to the Product's weight, color, consistency, micro-biological content, labeling and packaging are also set forth on Exhibit A. In the event that Exhibit A is incomplete, Products shall be manufactured and shipped in accordance with industry standards.

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.

  • Licensed Products Lessee will obtain no title to Licensed Products which will at all times remain the property of the owner of the Licensed Products. A license from the owner may be required and it is Lessee's responsibility to obtain any required license before the use of the Licensed Products. Lessee agrees to treat the Licensed Products as confidential information of the owner, to observe all copyright restrictions, and not to reproduce or sell the Licensed Products.

  • Licensed Product “Licensed Product” shall mean any article, composition, apparatus, substance, chemical material, method, process or service whose manufacture, use, or sale is covered or claimed by a Valid Claim within the Patent Rights. For clarity, a “Licensed Product” shall not include other product or material that (a) is used in combination with Licensed Product, and (b) does not constitute an article, composition, apparatus, substance, chemical material, method, process or service whose manufacture, use, or sale is covered or claimed by a Valid Claim within the Patent Rights.

  • Product The term “

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!